Cargando…

TRIB3 Promotes the Malignant Progression of Bladder Cancer: An Integrated Analysis of Bioinformatics and in vitro Experiments

BACKGROUND: Bladder cancer is a common malignant tumor characterized by high mortality and high management costs; however, it lacks useful molecular prognostic markers. Tribbles pseudokinase 3 (TRIB3) is a pseudokinase that participates in cell tumor progression and metabolism and whose function in...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Jieping, Lin, Jiaxing, An, Jun, Zhao, Yongkang, Jing, Siyang, Yu, Meng, Zhu, Yuyan, Yao, Yang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8033215/
https://www.ncbi.nlm.nih.gov/pubmed/33841505
http://dx.doi.org/10.3389/fgene.2021.649208
Descripción
Sumario:BACKGROUND: Bladder cancer is a common malignant tumor characterized by high mortality and high management costs; however, it lacks useful molecular prognostic markers. Tribbles pseudokinase 3 (TRIB3) is a pseudokinase that participates in cell tumor progression and metabolism and whose function in bladder cancer is not precisely known. MAIN METHODS: We downloaded transcriptome data and clinical data of bladder cancer from associated databases and extracted the expression matrix of TRIB3 for multiple bioinformatics analysis. RT-PCR detected the expression of TRIB3 in bladder cancer cells. After knockdown of TRIB3 with siRNA, we investigated TRIB3 function using CCK8, Cell Cycle and Transwell assays. KEY FINDINGS: Kaplan–Meier analysis of TRIB3 in the four cohorts showed that high expression of TRIB3 correlated with poor outcome. Expression of TRIB3 positively correlated with stage and grade and down-regulation of TRIB3 expression significantly inhibited proliferation, migration and cell cycle of bladder cancer cells. SIGNIFICANCE: TRIB3 is a potential prognostic marker and therapeutic target. It can be used to individualize the treatment of bladder cancer.